Pacira BioSciences, Inc. — Director's Dealing 2021

Jul 30, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Pacira BioSciences, Inc. (PCRX)
CIK: 0001396814
Period of Report: 2021-07-28

Reporting Person: Riker Lauren Bullaro (Vice President, Finance)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-07-28	Common Stock	M	2410	$10.81	Acquired	15562	Direct
2021-07-28	Common Stock	S	2410	$60.85	Disposed	13152	Direct
2021-07-29	Common Stock	M	90	$10.81	Acquired	13242	Direct
2021-07-29	Common Stock	S	90	$60.81	Disposed	13152	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-07-28	Stock Option (Right to Buy)	$10.81	M	2410	Disposed	2022-06-05	Common Stock (2410)	Direct
2021-07-29	Stock Option (Right to Buy)	$10.81	M	90	Disposed	2022-06-05	Common Stock (90)	Direct

Footnotes

F1: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

F2: Includes 421 shares of common stock acquired under the issuer's employee stock purchase plan in June 2021.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.81 to $60.858, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: The option vested and became exercisable as to 25% of the option shares on June 5, 2013 and vested as to the remaining shares in successive equal monthly installments for the subsequent 36 months.